Literature DB >> 15953767

Small hairpin RNAs efficiently inhibit hepatitis C IRES-mediated gene expression in human tissue culture cells and a mouse model.

Qian Wang1, Christopher H Contag, Heini Ilves, Brian H Johnston, Roger L Kaspar.   

Abstract

Treatment and prevention of hepatitis C virus (HCV) infections remain a major challenge for controlling this worldwide health problem; existing therapies are only partially effective and no vaccine is currently available. RNA interference offers the potential of a novel therapeutic approach for treating HCV infections. Toward this end, we evaluated small hairpin interfering RNAs (shRNAs) targeting the conserved internal ribosome entry site (IRES) element of the HCV genome for their ability to control gene expression in human cells and animals. We used a reporter gene plasmid in which firefly luciferase (fLuc) expression is dependent on the HCV IRES. Direct delivery of HCV IRES shRNAs efficiently blocked HCV IRES-mediated fLuc expression in transfected human 293FT cells as well as in a mouse model in which nucleic acids were delivered to liver cells by hydrodynamic transfection via the tail vein. These results indicate that shRNAs, delivered as RNA or expressed from viral or nonviral vectors, may be effective agents for the control of HCV and related viruses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15953767     DOI: 10.1016/j.ymthe.2005.04.014

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  20 in total

Review 1.  RNA interference and antiviral therapy.

Authors:  Yan Ma; Chu-Yan Chan; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

2.  Inhibition of hepatitis C IRES-mediated gene expression by 8-17 deoxyribozymes in human tissue culture cells.

Authors:  A V Vlassov; H Ilves; B H Johnston
Journal:  Dokl Biochem Biophys       Date:  2006 Sep-Oct       Impact factor: 0.788

3.  Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity.

Authors:  Qing Ge; Heini Ilves; Anne Dallas; Pavan Kumar; Joshua Shorenstein; Sergei A Kazakov; Brian H Johnston
Journal:  RNA       Date:  2009-12-01       Impact factor: 4.942

4.  Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes.

Authors:  Partha K Chandra; Anup K Kundu; Sidhartha Hazari; Sruti Chandra; Lili Bao; Tara Ooms; Gilbert F Morris; Tong Wu; Tarun K Mandal; Srikanta Dash
Journal:  Mol Ther       Date:  2012-05-22       Impact factor: 11.454

Review 5.  Hydrodynamic gene delivery and its applications in pharmaceutical research.

Authors:  Barbara Bonamassa; Li Hai; Dexi Liu
Journal:  Pharm Res       Date:  2010-12-30       Impact factor: 4.200

6.  Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs.

Authors:  Qing Ge; Anne Dallas; Heini Ilves; Joshua Shorenstein; Mark A Behlke; Brian H Johnston
Journal:  RNA       Date:  2009-11-30       Impact factor: 4.942

Review 7.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

8.  Stability study of unmodified siRNA and relevance to clinical use.

Authors:  Robyn P Hickerson; Alexander V Vlassov; Qian Wang; Devin Leake; Heini Ilves; Emilio Gonzalez-Gonzalez; Christopher H Contag; Brian H Johnston; Roger L Kaspar
Journal:  Oligonucleotides       Date:  2008-12

9.  Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy.

Authors:  Anne Dallas; Heini Ilves; Han Ma; Daniel J Chin; Ian Maclachlan; Klaus Klumpp; Brian H Johnston
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

Review 10.  Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site.

Authors:  Sergey M Dibrov; Jerod Parsons; Maia Carnevali; Shu Zhou; Kevin D Rynearson; Kejia Ding; Emily Garcia Sega; Nicholas D Brunn; Mark A Boerneke; Maria P Castaldi; Thomas Hermann
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.